People may have been exposed to TB at these two San Diego County shelters
SAN DIEGO (FOX 5/KUSI) — Residents, employees and volunteers who were at two local shelters earlier this year may have been exposed to tuberculosis, San Diego County health officials said Tuesday.
According to a news release from the county, the people may have been exposed to TB at the Father Joe's Villages Paul Mirabile Center located at 1501 Imperial Ave. and the San Diego Rescue Mission South County Lighthouse at 2400 Euclid Ave. in National City.
Coronado shoreline closed due to sewage from Tijuana River
The dates of potential exposure at the Paul Mirabile Center were between Feb. 14 to March 18 and from April 6 to May 7.
People may have been exposed to TB at the National City facility between March 28 to April 11.
County health officials said there is currently no evidence of a TB outbreak at the aforementioned sites, nor were the reported exposures linked with ones that were previously reported at shelters operated by Father Joe's Villages.
People experiencing homelessness have a higher risk of getting TB due to being in larger congregate settings, barriers to health care and other factors, according to the county.
TB is transmitted when someone inhales bacteria that are present in the air. This may occur when someone speaks, coughs, sings or breathes.
County health officials encourage anyone who spends a lot of time indoors with someone who is sick with TB to get tested for the disease.
About 175,000 residents across San Diego County have latent TB infection, which means they do not show symptoms but have tested positive.
About 5% to 10% of these cases may develop into active cases if they are not treated, the county stated.
The county is currently working with the affected shelters to notify those who may have been exposed.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
AAHI Partners with Quratis to Strengthen Global Vaccine Manufacturing and Accelerate Access to Lifesaving Vaccines
SEATTLE--(BUSINESS WIRE)--Access to Advanced Health Institute (AAHI), a global leader in translating high-impact science into scalable, field-ready vaccine solutions, today announced an exciting new partnership with Quratis, a premier biotechnology company and advanced Contract Development and Manufacturing Organization (CDMO). This collaboration marks a pivotal step forward in breaking through barriers in global health equity around the world. Under this strategic alliance, Quratis has been selected as AAHI's preferred manufacturer for high-quality pre-clinical and clinical vaccine supplies, with the capacity to expand into commercial-scale production for global markets. This collaboration will accelerate the development of AAHI's innovative vaccine candidates targeting deadly diseases such as tuberculosis, and of vaccines that rely on AAHI's vaccine adjuvants to provide protection against malaria, HIV, and other global health threats. Quratis brings a world-class GMP-certified bioplant and cutting-edge CDMO expertise in biopharmaceutical raw material development, process optimization, and finished pharmaceutical manufacturing. By designating Quratis as preferred partner, AAHI strengthens both its scientific capabilities and access to scalable, cost-effective production of its groundbreaking vaccine formulations—including dry vaccines that eliminate cold chain dependencies and needle-free delivery systems for superior respiratory protection. The partnership ensures a seamless supply chain platform, enabling swift clinical development and broader deployment to the world's most vulnerable populations. "Partnering with Quratis is a very important step in AAHI's strategy to advance practical, life-saving vaccines, that can be deployed at scale where they're needed most,' said Keeley Foley, CEO of AAHI. 'Quartis' innovative cutting edge, safe, world-class CDMO capabilities makes it possible for AAHI to deliver on our mission – and helps ensure our efforts to combat infectious diseases and foster health autonomy worldwide. Together, we're not just manufacturing vaccines—we're delivering an important mission to revolutionize global health." Quratis, renowned for its global innovation in healthcare, brings unparalleled expertise in vaccine development and manufacturing to the table. With a track record of success in TB and COVID-19 vaccines like QTP101 and QTP104, Quratis' advanced processes will enhance AAHI's pipeline, ensuring high-quality, efficient production from pre-clinical stages through clinical trials. "We are honored and thrilled to join forces with AAHI, a pioneer in immune-enhancing technologies and sustainable vaccine solutions," said Soung Joon Kim, CEO of Quratis. "This partnership aligns perfectly with our vision of making people happy and healthy through borderless healthcare innovations. By supporting AAHI's pipeline, we expect to create value not only for global health, but also for our shareholders through long-term growth opportunities.' The partnership builds on existing collaborations, including the co-development of the ID93+GLA-SE tuberculosis vaccine candidate (QTP101), and underscores a shared commitment to strengthening international vaccine supply chains, advancing equitable access, and fostering worldwide manufacturing capacity for sustainable program deployment. For more information about this partnership or to explore collaboration opportunities, and order pre clinical materials please contact info@ About Access to Advanced Health Institute (AAHI) Access to Advanced Health Institute (AAHI) is a global leader in developing practical, cost-effective vaccines to combat deadly diseases such as tuberculosis, malaria, and HIV. With a mission to translate high-impact science into scalable, field-ready solutions, AAHI breaks through barriers in global health by creating innovative vaccine formulations, building worldwide manufacturing capacity, and fostering partnerships to ensure sustainable, equitable health outcomes. For more information, visit or contact us at info@ About Quratis Quratis Inc. is a leading biopharmaceutical company specializing in innovative vaccine development and advanced biologics manufacturing. With a state-of-the-art GMP facility and strong global partnerships, Quratis is at the forefront of developing next-generation vaccines against infectious diseases, including tuberculosis, COVID-19, schistosomiasis, and neglected tropical diseases. In addition to its core vaccine pipeline, Quratis offers superior CDMO capabilities, including expertise in mRNA–LNP drug delivery platforms that provide seamless bench-to-field support from research through commercial production. By combining cutting-edge R&D with scalable manufacturing, Quratis is committed to delivering high-quality, accessible, and life-saving solutions to patients worldwide. For more information, visit
Yahoo
14 hours ago
- Yahoo
Active TB case found in Singapore preschool staff; no transmission detected, CDA says
SINGAPORE, Aug 21 — A staff member at MindChamps PreSchool (East Coast) has been clinically diagnosed with active tuberculosis (TB), prompting screenings at two preschools, according to Singapore's CNA. This case involves a household contact of a previously reported TB patient, CNA reported. The Communicable Diseases Agency (CDA) said early results showed no evidence of TB transmission within both MindChamps and MapleBear Toa Payoh, and no children have tested positive to date. The staff member was diagnosed on Aug 18 and, at this stage, is asymptomatic, on medical leave, and will be non-infectious after two weeks of treatment. As a precaution, CDA has contacted both preschools to identify staff and students with close and prolonged contact with the individual, offering them TB screening. In total, 115 people have been tested: 93 were screened onsite, 21 have scheduled appointments at the National TB Screening Centre (NTBSC), and one was screened at a private lab. CNA reported that of those screened onsite, 80 individuals (86 per cent) tested negative. Eight people—including six children and two staff—had indeterminate results, meaning TB infection status remains inconclusive; this is not uncommon in young children. These individuals will undergo repeat testing between Aug 19 and 27 at the NTBSC. A second round of screening is set for mid-September at MapleBear Toa Payoh—10 weeks after exposure—to detect any latent infections not yet evident, in line with national guidelines, CNA added. Separately, four staff screened onsite tested positive in blood tests, likely indicating latent TB infection. These individuals have been referred to NTBSC for further evaluation, and if active disease is ruled out, they will be offered preventive treatment. CDA said all previously screened parents and staff have been informed of results and given NTBSC follow-up appointments as necessary. The agency continues to monitor the situation closely and is working with both preschools to address concerns, providing information sheets on TB screening and treatment, CNA said.
Yahoo
a day ago
- Yahoo
TB screenings at two pre-schools after staff member diagnosed in July
SINGAPORE - Tuberculosis (TB) screenings will be conducted at two pre-schools after an individual working at both locations was found to have been diagnosed with the bacterial disease, the Communicable Diseases Agency (CDA) has said. In response to queries, CDA said on Aug 13 it was notified on July 15 of the positive diagnosis of a staff member who worked at MapleBear Toa Payoh and MindChamps PreSchool's East Coast branch. It then began contact tracing to 'ensure early detection and treatment, and to curtail the spread of TB', the agency said, adding that it conducted a site visit to determine which individuals were required to undergo screenings. For this particular case, CDA said only those found to have 'close and prolonged' contact with the staff member would have to be screened. They include both children and staff members. An onsite screening at MindChamps PreSchool was carried out on Aug 13, while a separate one for MapleBear Toa Payoh has been scheduled for Aug 15. CDA said there is a gap between exposure to the staff member and the screenings because it can take several weeks for the body to develop a detectable immune response. A second round of screenings slated for mid-September will be carried out at MapleBear Toa Payoh, 10 weeks after the date of the last exposure to the affected staff member. The agency said this is in line with national and international guidelines and would help to identify infected individuals who may not have been picked out during the first screening. MindChamps PreSchool's East Coast branch, however, will be put through only one screening because of the difference in exposure periods, CDA added. On the status of the affected staff member, CDA said the person is recovering well and currently non-infectious. The staff member is also continuing to receive treatment. Those with active cases of TB are usually non-infectious within two weeks upon being treated, it said, adding that the disease is endemic in Singapore. A disease that is endemic is one that remains permanently in the community. 'TB is curable and its spread is preventable. People with latent TB do not have symptoms and cannot spread tuberculosis to others,' said CDA. 'Parents of children identified as close contacts should follow instructions for screening for their children and, if needed, treatment.' It added: 'The child is safe to continue with normal activities unless advised otherwise. Their household members, who are not identified as close contacts, do not need to take any special precautions.' As for those who require preventive medication to reduce the risk of developing tuberculosis, CDA said it will arrange appointments and chest X-rays at the National TB Screening Centre for them. A spokesperson for the Early Childhood Development Agency (ECDA) said it was notified on July 17 about the TB diagnosis. The spokesperson said that when there is any known or suspected case of the disease, pre-schools are required to promptly inform ECDA, parents and CDA. The pre-schools will also need to implement hygiene, cleaning and disinfection measures. The spokesperson added that as part of regular health surveillance protocols, pre-schools also carry out daily temperature and health checks on all children, staff and visitors as soon as they arrive. They are also not supposed to admit any individuals who are unwell or display symptoms of infectious diseases. The Straits Times has contacted both the affected pre-schools for more information. The last time a TB screening was reported as having been conducted at a pre-school was in 2019, after an individual at a PAP Community Foundation (PCF) Sparkletots in Bukit Batok was diagnosed with the disease. Source: The Straits Times © SPH Media Limited. Permission required for reproduction Discover how to enjoy other premium articles here
